An expert opinion on the pharmacological interventions for Disruptive Mood Dysregulation Disorder (DMDD)

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Press; 2013.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th-TR ed. Washington, DC: American Psychiatric Press; 2022.
   Google Scholar
• Hendrickson B, Girma M, Miller L. Review of the clinical approach to the treatment of disruptive mood dysregulation disorder. Int Rev Psychiatry. 2020;32(3):202–211. doi: 10.1080/09540261.2019.1688260
   PubMed Web of Science ®Google Scholar
• Rao U. DSM-5: disruptive mood dysregulation disorder. Asian J Psychiatr. 2014;11:119–23. doi: 10.1016/j.ajp.2014.03.002
   PubMedGoogle Scholar
• Bruno A, Celebre L, Torre G, et al. Focus on disruptive mood dysregulation disorder: a review of the literature. Psychiatry Res. 2019;279:323–330. doi: 10.1016/j.psychres.2019.05.043
   PubMed Web of Science ®Google Scholar
• Leibenluft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry. 2011;168(2):129–42. doi: 10.1176/appi.ajp.2010.10050766
   PubMed Web of Science ®Google Scholar
• Moreno C, Laje G, Blanco C, et al. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry. 2007;64(9):1032–1039. doi: 10.1001/archpsyc.64.9.1032
   PubMed Web of Science ®Google Scholar
• Stringaris A, Baroni A, Haimm C, et al. Pediatric bipolar disorder versus severe mood dysregulation: risk for manic episodes on follow-up. J Am Acad Child Adolesc Psychiatry. 2010;49(4):397–405. doi: 10.1097/00004583-201004000-00014
   PubMed Web of Science ®Google Scholar
• Brotman MA, Schmajuk M, Rich BA, et al. Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biol Psychiatry. 2006;60(9):991–7. doi: 10.1016/j.biopsych.2006.08.042
   PubMed Web of Science ®Google Scholar
• Baweja R, Mayes SD, Hameed U, et al. Disruptive mood dysregulation disorder: current insights. Neuropsychiatr Dis Treat. 2016;12:2115–2124. doi: 10.2147/NDT.S100312
   PubMed Web of Science ®Google Scholar
• Martin SE, Hunt JI, Mernick LR, et al. Temper loss and persistent irritability in preschoolers: implications for diagnosing disruptive mood dysregulation disorder in early childhood. Child Psychiatry Hum Dev. 2017;48(3):498–508. doi: 10.1007/s10578-016-0676-x
   PubMed Web of Science ®Google Scholar
• Tufan E, Topal Z, Demir N, et al. Sociodemographic and clinical features of disruptive mood dysregulation disorder: a chart review. J Child Adolesc Psychopharmacol. 2016;26(2):94–100. doi: 10.1089/cap.2015.0004
   PubMed Web of Science ®Google Scholar
• Brotman MA, Kircanski K, Leibenluft E. Irritability in children and adolescents. Annu Rev Clin Psychol. 2017;13(1):317–341. doi: 10.1146/annurev-clinpsy-032816-044941
   PubMedGoogle Scholar
• Carlson GA, Klein DN. How to understand divergent views on bipolar disorder in youth. Annu Rev Clin Psychol. 2014;10(1):529–551. doi: 10.1146/annurev-clinpsy-032813-153702
   PubMedGoogle Scholar
• Goldstein BI, Birmaher B, Carlson GA, et al. The international society for bipolar disorders task force report on pediatric bipolar disorder: knowledge to date and directions for future research. Bipolar Disord. 2017;19(7):524–543. doi: 10.1111/bdi.12556
   PubMed Web of Science ®Google Scholar
• Copeland WE, Angold A, Costello EJ, et al. Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. Am J Psychiatry. 2013;170(2):173–9. doi: 10.1176/appi.ajp.2012.12010132
   PubMed Web of Science ®Google Scholar
• Althoff RR, Crehan ET, He JP, et al. Disruptive mood dysregulation disorder at ages 13-18: results from the national comorbidity survey-adolescent supplement. J Child Adolesc Psychopharmacol. 2016;26(2):107–113.
   PubMed Web of Science ®Google Scholar
• Shah K, Trivedi C, Kamrai D, et al. Suicide in adolescents with mood disorders. Eur Psychiatry. 2022;65(Suppl 1):S141.
   Google Scholar
• Copeland WE, Shanahan L, Egger H, et al. Adult diagnostic and functional outcomes of DSM-5 disruptive mood dysregulation disorder. Am J Psychiatry. 2014;171(6):668–74. doi: 10.1176/appi.ajp.2014.13091213
   PubMed Web of Science ®Google Scholar
• Munhoz TN, Santos IS, Barros AJD, et al. Perinatal and postnatal risk factors for disruptive mood dysregulation disorder at age 11: 2004 pelotas birth cohort study. J Affect Disord. 2017;215:263–268. doi: 10.1016/j.jad.2017.03.040
   PubMed Web of Science ®Google Scholar
• Dougherty LR, Barrios CS, Carlson GA, et al. Predictors of later psychopathology in young children with disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2017;27(5):396–402. doi: 10.1089/cap.2016.0144
   PubMed Web of Science ®Google Scholar
• Topal Z, Demir N, Tufan E, et al. Emotional and cognitive conflict resolution and disruptive mood dysregulation disorder in adolescent offspring of parents diagnosed with major depressive disorder, bipolar disorder, and matched healthy controls. Nord J Psychiatry. 2021;75(6):427–436.
   PubMed Web of Science ®Google Scholar
• Sacco R, Camilleri N, Eberhardt J, et al. A systematic review and meta-analysis on the prevalence of mental disorders among children and adolescents in Europe. Eur Child Adolesc Psychiatry. 2022;30:1–18. doi: 10.1007/s00787-022-02131-2
   Google Scholar
• Mayes SD, Waxmonsky JD, Calhoun SL, et al. Disruptive mood dysregulation disorder symptoms and association with oppositional defiant and other disorders in a general population child sample. J Child Adolesc Psychopharmacol. 2016;26(2):101–6. doi: 10.1089/cap.2015.0074
   PubMed Web of Science ®Google Scholar
• Roy AK, Klein RG, Angelosante A, et al. Clinical features of young children referred for impairing temper outbursts. J Child Adolesc Psychopharmacol. 2013;23(9):588–96. doi: 10.1089/cap.2013.0005
   PubMed Web of Science ®Google Scholar
• Brænden A, Coldevin M, Zeiner P, et al. Executive function in children with disruptive mood dysregulation disorder compared to attention-deficit/hyperactivity disorder and oppositional defiant disorder, and in children with different irritability levels. Eur Child Adolesc Psychiatry. 2023;21:1–11. doi: 10.1007/s00787-023-02143-6
   Google Scholar
• Carlson GA, Pataki C. Disruptive mood dysregulation disorder among children and adolescents. Focus (Am Psychiatr Publ). 2016;14(1):20–25. doi: 10.1176/appi.focus.20150039
   PubMedGoogle Scholar
• Mulraney M, Silk TJ, Gulenc A, et al. Persistence of disruptive mood dysregulation disorder in children with attention-deficit/hyperactivity disorder. J Affect Disord. 2021;278:502–505. doi: 10.1016/j.jad.2020.09.109
   PubMed Web of Science ®Google Scholar
• Ivanović I. Psychiatric comorbidities in children with ASD: autism centre experience. Front Psychiatry. 2021;12:673169. doi: 10.3389/fpsyt.2021.673169
   PubMed Web of Science ®Google Scholar
• Benarous X, Consoli A, Guilé JM, et al. Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD. Eur Child Adolesc Psychiatry. 2017;26(1):5–23. doi: 10.1007/s00787-016-0907-5
   PubMed Web of Science ®Google Scholar
• Findling RL, Zhou X, George P, et al. Diagnostic trends and prescription patterns in disruptive mood dysregulation disorder and bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2022;61(3):434–445. doi: 10.1016/j.jaac.2021.05.016
   PubMed Web of Science ®Google Scholar
• Rajkumar RP. Antipsychotics in the management of disruptive behavior disorders in children and adolescents: an update and critical review. Biomedicines. 2022;10(11):2818. doi: 10.3390/biomedicines10112818
   PubMed Web of Science ®Google Scholar
• Le J, Feygin Y, Creel L, et al. Trends in diagnosis of bipolar and disruptive mood dysregulation disorders in children and youth. J Affect Disord. 2020;264:242–248. doi: 10.1016/j.jad.2019.12.018
   PubMed Web of Science ®Google Scholar
• Stringaris A, Vidal-Ribas P, Brotman MA, et al. Practitioner review: definition, recognition, and treatment challenges of irritability in young people. J Child Psychol Psychiatr. 2018;59(7):721–739. doi: 10.1111/jcpp.12823
   PubMed Web of Science ®Google Scholar
• Tourian L, LeBoeuf A, Breton JJ, et al. Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. J Can Acad Child Adolesc Psychiatry. 2015;24(1):41–54.
   PubMedGoogle Scholar
• Gupta M, Gupta N. Disruptive mood dysregulation disorder: does variance in treatment responses also add to the conundrum? The widening gap in the evidence is a signal needing attention. CNS Spectr. 2022;27(6):659–661. doi: 10.1017/S1092852921000985
   PubMed Web of Science ®Google Scholar
• Benarous X, Renaud J, Breton JJ, et al. Are youths with disruptive mood dysregulation disorder different from youths with major depressive disorder or persistent depressive disorder? J Affect Disord. 2020;265:207–215. doi: 10.1016/j.jad.2020.01.020
   PubMed Web of Science ®Google Scholar
• Grau K, Plener PL, Hohmann S, et al. Prevalence rate and course of symptoms of disruptive mood dysregulation disorder (DMDD). Z Kinder Jugendpsychiatr Psychother. 2018;46(1):29–38.
   PubMed Web of Science ®Google Scholar
• Baweja R, Belin PJ, Humphrey HH, et al. The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/Hyperactivity disorder and disruptive mood dysregulation disorder across home and school. J Child Adolesc Psychopharmacol. 2016;26(2):154–63. doi: 10.1089/cap.2015.0053
   PubMed Web of Science ®Google Scholar
• Winters DE, Fukui S, Leibenluft E, et al. Improvements in irritability with open-label methylphenidate treatment in youth with comorbid attention deficit/hyperactivity disorder and disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2018;28(5):298–305. doi: 10.1089/cap.2017.0124
   PubMed Web of Science ®Google Scholar
• Benarous X, Ferrafiat V, Zammit J, et al. Effective use of atomoxetine to treat six inpatient youths with disruptive mood dysregulation disorder without attention deficit disorder. CNS Spectr. 2020;25(4):455–457. doi: 10.1017/S1092852919001020
   PubMed Web of Science ®Google Scholar
• Dickstein DP, Towbin KE, Van Der Veen JW, et al. Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. J Child Adolesc Psychopharmacol. 2009;19(1):61–73.
   PubMed Web of Science ®Google Scholar
• Krieger FV, Pheula GF, Coelho R, et al. An open-label trial of risperidone in children and adolescents with severe mood dysregulation. J Child Adolesc Psychopharmacol. 2011;21(3):237–43. doi: 10.1089/cap.2010.0123
   PubMed Web of Science ®Google Scholar
• Pan PY, Fu AT, Yeh CB. Aripiprazole/Methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: an open-label study. J Child Adolesc Psychopharmacol. 2018;28(10):682–689. doi: 10.1089/cap.2018.0068
   PubMed Web of Science ®Google Scholar
• Towbin K, Vidal-Ribas P, Brotman MA, et al. A double-blind randomized placebo-controlled trial of citalopram adjunctive to stimulant medication in youth with chronic severe irritability. J Am Acad Child Adolesc Psychiatry. 2020;59(3):350–361. doi: 10.1016/j.jaac.2019.05.015
   PubMed Web of Science ®Google Scholar
• Parmar A, Vats D, Parmar R, et al. Role of naltrexone in management of behavioral outbursts in an adolescent male diagnosed with disruptive mood dysregulation disorder. J Child Adolesc Psychopharmacol. 2014;24(10):594–5. doi: 10.1089/cap.2014.0072
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Hirsch L, Gardner D, et al. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42–51.
   PubMed Web of Science ®Google Scholar
• Gorman DA, Gardner DM, Murphy AL, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60(2):62–76. doi: 10.1177/070674371506000204
   PubMed Web of Science ®Google Scholar
• Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253–261.
   PubMed Web of Science ®Google Scholar
• Vaudreuil C, Farrell A, Wozniak J. Psychopharmacology of treating explosive behavior. Child Adolesc Psychiatr Clin N Am. 2021;30(3):537–560. doi: 10.1016/j.chc.2021.04.006
   PubMed Web of Science ®Google Scholar
• Cortese S. Evidence-based prescribing of medications for ADHD: where are we in 2023? Expert Opin Pharmacother. 2023 Mar;24(4):425–434. doi: 10.1080/14656566.2023.2169604
   PubMed Web of Science ®Google Scholar
• Pagliaccio D, Wiggins JL, Adleman NE, et al. Behavioral and neural sustained attention deficits in disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2017;56(5):426–435. doi: 10.1016/j.jaac.2017.02.008
   PubMed Web of Science ®Google Scholar
• Breaux R, Baweja R, Eadeh HM, et al. Systematic review and meta-analysis: pharmacological and nonpharmacological interventions for persistent nonepisodic irritability. J Am Acad Child Adolesc Psychiatry. 2023;62(3):318–334. doi: 10.1016/j.jaac.2022.05.012
   PubMed Web of Science ®Google Scholar
• Breaux R, Dunn NC, Swanson CS, et al. A mini-review of pharmacological and psychosocial interventions for reducing irritability among youth with ADHD. Front Psychiatry. 2022;13:794044. doi: 10.3389/fpsyt.2022.794044
   PubMed Web of Science ®Google Scholar
• Loy JH, Merry SN, Hetrick SE, et al. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017;8(8):CD008559. doi: 10.1002/14651858.CD008559.pub3
   PubMedGoogle Scholar
• Harrison JN, Cluxton-Keller F, Gross D. Antipsychotic medication prescribing trends in children and adolescents. J Pediatr Health Care. 2012;26(2):139–45. doi: 10.1016/j.pedhc.2011.10.009
   PubMed Web of Science ®Google Scholar
• Miral S, Gencer O, Inal-Emiroglu FN, et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry. 2008;17(1):1–8. doi: 10.1007/s00787-007-0620-5
   PubMed Web of Science ®Google Scholar
• Pappadopulos E, Woolston S, Chait A, et al. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry. 2006;15(1):27–39.
   PubMedGoogle Scholar
• Iasevoli F, Barone A, Buonaguro EF, et al. Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opin Drug Saf. 2020;19(11):1419–1444. doi: 10.1080/14740338.2020.1820985
   PubMed Web of Science ®Google Scholar
• D’Alò GL, De Crescenzo F, Amato L. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis. Health Qual Life Outcomes. 2021;19(1):33. doi: 10.1186/s12955-021-01669-0
   PubMed Web of Science ®Google Scholar
• Hoekstra PJ, Dietrich A. First do no harm: use off-label antipsychotic medication in children and adolescents with great caution. Eur Child Adolesc Psychiatry. 2022;31(1):1–3. doi: 10.1007/s00787-022-01950-7
   Web of Science ®Google Scholar
• Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629–35. doi: 10.1016/j.euroneuro.2009.04.008
   PubMed Web of Science ®Google Scholar
• Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(Suppl 7):29–40.
   PubMedGoogle Scholar
• Raballo A, Poletti M, Preti A. Antipsychotics in children and adolescents at clinical high risk for psychosis. J Am Acad Child Adolesc Psychiatry. 2022;61(3):354–356. doi: 10.1016/j.jaac.2021.05.025
   PubMed Web of Science ®Google Scholar
• Austerman J. ADHD and behavioral disorders: assessment, management, and an update from DSM-5. Cleve Clin J Med. 2015;82(11 Suppl 1):S2–S7. doi: 10.3949/ccjm.82.s1.01
   PubMedGoogle Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry. 2014;53(2):153–173. doi: 10.1016/j.jaac.2013.11.009
   PubMed Web of Science ®Google Scholar
• Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol. 2013;23(5):308–319. doi: 10.1089/cap.2013.0028
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bell E. Fake views: DMDD, indeed! Aust N Z J Psychiatry. 2019;53(7):706–710. doi: 10.1177/0004867419863162
   PubMed Web of Science ®Google Scholar
• Isbell LM, Kang S, Barysky G, et al. Stigmatizing attitudes toward Disruptive Mood Dysregulation Disorder (DMDD) in parents vs. non-parents: effects of medication and genetic etiology. PloS One. 2022;17(9):e0274185. doi: 10.1371/journal.pone.0274185
   PubMed Web of Science ®Google Scholar
• Roy AK. Editorial: a call for developmental psychopathology approaches to diagnostic nosology. J Am Acad Child Adolesc Psychiatry. 2021;60(3):343–345. doi: 10.1016/j.jaac.2020.07.008
   PubMed Web of Science ®Google Scholar
• Laporte PP, Matijasevich A, Munhoz TN, et al. Disruptive mood dysregulation disorder: symptomatic and syndromic thresholds and diagnostic operationalization. J Am Acad Child Adolesc Psychiatry. 2021;60(2):286–9. 10.1016/j.jaac.2019.12.008
   PubMed Web of Science ®Google Scholar
• Havens JF, Marr MC, Hirsch E. Editorial: from bipolar disorder to disruptive mood dysregulation disorder: challenges to diagnostic and treatment specificity in traumatized youths. J Am Acad Child Adolesc Psychiatry. 2022;61(3):364–365. doi: 10.1016/j.jaac.2021.07.012
   PubMed Web of Science ®Google Scholar
• Mitchell RH, Timmins V, Collins J, et al. Prevalence and correlates of disruptive mood dysregulation disorder among adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2016;26(2):147–153.
   PubMed Web of Science ®Google Scholar
• Noller DT. Distinguishing disruptive mood dysregulation disorder from pediatric bipolar disorder. JAAPA. 2016;29(6):25–8. doi: 10.1097/01.JAA.0000483092.35899.a7
   PubMedGoogle Scholar
• Freeman AJ, Youngstrom EA, Youngstrom JK, et al. Disruptive mood dysregulation disorder in a community mental health clinic: prevalence, comorbidity and correlates. J Child Adolesc Psychopharmacol. 2016;26(2):123–30. doi: 10.1089/cap.2015.0061
   PubMed Web of Science ®Google Scholar
• Parker G, Tavella G. Disruptive mood dysregulation disorder: a critical perspective. Can J Psychiatry. 2018;63(12):813–815. doi: 10.1177/0706743718789900
   PubMed Web of Science ®Google Scholar
• Axelson D. Taking disruptive mood dysregulation disorder out for a test drive. Am J Psychiatry. 2013;170(2):136–9. doi: 10.1176/appi.ajp.2012.12111434
   PubMed Web of Science ®Google Scholar
• Perepletchikova F, Nathanson D, Axelrod SR, et al. Randomized clinical trial of dialectical behavior therapy for preadolescent children with disruptive mood dysregulation disorder: feasibility and outcomes. J Am Acad Child Adolesc Psychiatry. 2017;56(10):832–40. doi: 10.1016/j.jaac.2017.07.789
   PubMed Web of Science ®Google Scholar
• Linke J, Kircanski K, Brooks J, et al. Exposure-based cognitive-behavioral therapy for disruptive mood dysregulation disorder: an evidence-based case study. Behav Ther. 2020;51(2):320–333. doi: 10.1016/j.beth.2019.05.007
   PubMed Web of Science ®Google Scholar
• Andrade BF, Aitken M, Brodkin S, et al. Multiple needs and multiple treatments. What’s a clinician to do? Update on the psychosocial treatment of disruptive behaviors in childhood. Curr Opin Psychiatry. 2022;35(6):409–416.
   PubMed Web of Science ®Google Scholar
• Derella OJ, Burke JD, Romano-Verthelyi AM, et al. Feasibility and acceptability of a brief cognitive-behavioral group intervention for chronic irritability in youth. Clin Child Psychol Psychiatry. 2020;25(4):778–789. doi: 10.1177/1359104520918331
   PubMed Web of Science ®Google Scholar
• Meyers E, DeSerisy M, Roy AK. Disruptive Mood Dysregulation Disorder (DMDD): An RDoC perspective. J Affect Disord. 2017;216:117–122.
   PubMed Web of Science ®Google Scholar
• Onishi Y, Mikami K, Kimoto K, et al. Second-generation antipsychotic drugs for children and adolescents. J Nippon Med Sch. 2021;88(1):10–16. doi: 10.1272/jnms.JNMS.2021_88-108
   PubMed Web of Science ®Google Scholar
• Shafiq S, Pringsheim T. Using antipsychotics for behavioral problems in children. Expert Opin Pharmacother. 2018;19(13):1475–1488. doi: 10.1080/14656566.2018.1509069
   PubMed Web of Science ®Google Scholar
• Duffy A, Grof P. Lithium treatment in children and adolescents. Pharmacopsychiatry. 2018;51(5):189–193. doi: 10.1055/a-0575-4179
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. U.S. National Library of medicine; [cited 2023 Aug 23]. Available from: https://classic.clinicaltrials.gov/ct2/results?cond=Disruptive+Mood+Dysregulation+Disorder&term=&cntry=&state=&city=&dist=.
   Google Scholar
• ClinicalTrials.gov [Internet]. U.S. National Library of medicine; [cited 2023 Aug 23]. Available from: https://clinicaltrials.gov/study/NCT02824627
   Google Scholar
• ClinicalTrials.gov [Internet]. U.S. National Library of medicine; [cited 2023 Aug 23]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04820946?cond=Disruptive+Mood+Dysregulation+Disorder&draw=2&rank=3.
   Google Scholar